Global OnceMix results
Dr. Sanjay Kalra
Faculty, Indian Thyroid Society
Consultant, Bharti Hospital
Karnal, Haryana, India
Kalra教授介绍了一项开放标签、随机、平行、国际多中心研究（OnceMix），该研究比较门冬胰岛素30每日1次方案与甘精胰岛素每日1次方案作为胰岛素起始策略的疗效和安全性。对亚洲人群为期26周的观察显示，与甘精胰岛素相比，门冬胰岛素30组HbA1c降幅更大（-1.25%对-0.9%，P=0.015），餐后及睡前血糖控制更好。两组严重低血糖发生率均较低（1.3%对2.5%，P=NS）。对于FPG、体重、使用剂量指标，两组相似。这一结果证实，与甘精胰岛素相比，每日1次门冬胰岛素30具有更好的降糖效果，且安全性与之相似。
Current recommendations for the treatment of type 2 diabetes reflect its pathophysiology.Intervention at the time of diagnosis, which is commonly a combination of lifestyle modifications and metformin, followed by timely initiation and intensification of insulin is a mean to achieving glycaemic control. Previous exploratory trials have compared efficacy and safety of NovoMix® 30 twice-daily with once-daily insulin glargine.
However, no direct comparison has been performed between NovoMix® 30 and insulin glargine, both administered once daily in type 2 diabetes. During this session, Dr Kalra will present the OnceMix study results recently published in Current Medical Research and Opinion (2009) where the efficacy and safety of NovoMix® 30 was compared to insulin glargine in a once daily regimen in combination with metformin and glimepiride in patients inadequately controlled on oral antidiabetics.
OnceMix 研究：诺和锐30全球研究结果
查看分页PPT： http://meeting.dxy.cn/2009asia_summit/article/i9912.html
